Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.57 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280695 | 0.86 | OPRM1 (0.65) | OPRM1OPRK1OPRL1SLC6A4MEN1 | |
| SCHEMBL14280698 | 0.81 | OPRL1 (0.76) | OPRM1OPRK1OPRL1MEN1KMT2A | |
| SCHEMBL4880602 | 0.78 | OPRM1 (0.75) | OPRM1OPRK1OPRL1SLC6A4 | |
| Hydrochloric Acid SCHEMBL7868006 | 0.74 | OPRM1 (0.62) | OPRM1OPRK1OPRL1SLC6A4 | |
| SCHEMBL6593968 | 0.73 | OPRM1 (0.54) | OPRM1OPRK1OPRL1SLC6A4 | |
| SCHEMBL14280696 | 0.73 | OPRL1 (1.00) | OPRM1OPRK1OPRL1SLC6A4ACHE | |
| SCHEMBL14280686 | 0.72 | OPRL1 (1.00) | OPRM1OPRK1OPRL1SLC6A4 | |
| SCHEMBL14315765 | 0.71 | CXCR4 (0.39) | OPRM1OPRK1OPRL1MEN1KMT2A | |
| SCHEMBL7214363 | 0.71 | OPRL1 (0.76) | OPRM1OPRK1OPRL1SLC6A4 | |
| SCHEMBL5387561 | 0.71 | OPRM1 (0.62) | OPRM1OPRK1OPRL1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| WO-2007050381-A2 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | OGFRL1, OPRL1, ORMDL3 | OPRM1 11/4885OPRK1 5/4885OPRL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.